BDCA-04 / BioCardia - LARVOL DELTA

BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications (BioSpace) - "BioCardia®, Inc...announces that the United States Patent Office has granted Patent Number 11,642,377: titled, 'Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications', with a patent term that will expire in 2039. The patent specification details methods for selecting and expanding NK1R+ Mesenchymal Stem Cells (MSC) and their use to treat a number of diseases. The first allowed claim protects using these cells to treat cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging. There are seventeen additional claims allowed in this patent issuance."

Patent • Pulmonary Disease • Respiratory Diseases